In fact, metuximab and metuzumab are two anti-human EMMPRIN antibodies that are currently in use or in clinical trials for the treatment of hepatocellular carcinoma (HCC) (31) and non-small cell lung carcinoma (NSCLC) (32), respectively, indicating the feasibility of EMMPRIN as a target. Here, BSG is linked to hepatocellular carcinoma.